On June 22, 2021 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported its inaugural event, NeXT Level Biomarkers Symposium, which will showcase novel research into emerging biomarkers using the Personalis NeXT Platform (Press release, Personalis, JUN 22, 2021, View Source [SID1234584247]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This event will detail the latest research from Personalis as well as a case study done in collaboration with the Parker Institute for Cancer Immunotherapy. Presentations from Personalis will focus on recently published research into HLA loss of heterozygosity, neoantigen prediction, as well as Personalis’ novel composite biomarker, the Neoantigen Presentation Score (NEOPS). In addition, Dr. Theresa LaVallee will be presenting findings from the PRINCE trial based on data developed and analyzed in collaboration with Personalis.
The agenda for NeXT Level Biomarkers Symposium will cover:
Biomarker Discovery with ImmunoID NeXT Platform
Exploring HLA LOH with the DASH (Deletion of Allele-Specific HLAs) Algorithm
Neoantigen Binding Prediction and Biomarker Discovery with SHERPA
Composite Biomarkers and our Neoantigen Presentation Score (NEOPS)
Parker Institute Case Study: The PRINCE Trial
NeXT Liquid Biopsy Overview and Review of AACR (Free AACR Whitepaper) Data
NeXT Dx and Companion Diagnostics (CDx) with Personalis
"We are excited to share our latest technology and product advances with our partners," said Richard Chen, MD, Personalis CSO. "Given the complex biology underlying cancer progression and response to treatment, our mission at Personalis is to provide broader, more comprehensive molecular profiling and testing for each patient’s cancer, thereby giving biopharma, physicians, and patients the information they need for precision oncology now and with an eye to the future. These new technologies help further that mission."